December 2 CBPP Spotlight | Case-Based Peer Perspectives Spotlight Live

Rationale Taken From Trial Data for Using Daratumumab in Multiple Myeloma

January 19, 2021

Clinical Articles

During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Alex Mejia-Garcia, MD, medical oncologist, Cleveland Clinic, discussed the use of daratumumab as treatment of multiple myeloma. The discussion was based on the case scenario of a 51-year-old patient.

Sequencing of CD19-Directed Therapy Is Still Up for Debate

January 17, 2021

Clinical Articles

Gilles Salles, MD, PhD, discussed sequencing of CD-19 directed therapies for a 74-year-old patient with diffuse large B-cel lymphoma during a Targeted Oncology Case-Based Peer Perspective Roundtable event.

Details of Different Therapies and Modalities Decide Treatment of CLL in the Second Line

January 13, 2021

Clinical Articles

For the second-line treatment of patients with chronic lymphocytic leukemia, the armamentarium includes many therapies and strategies. Danielle Brander, MD, assistant professor of Medicine at Duke Cancer Institute, discussed how to select treatment for patients during a Targeted Oncology Case-Based Peer Perspectives event.

Expert Discusses Genomic Testing and Trials Pertinent to Treating Prostate Cancer

January 12, 2021

Clinical Articles

During a Targeted Oncology Case-Based Peer Perspectives event, Arash Rezazadeh Kalebasty, MD, discussed genomic testing and evidence-based treatment of a 60-year-old male patient with prostate cancer.

Systemic Therapy Remains a Successful Strategy for Patients Refusing Surgery for CSCC

January 11, 2021

Clinical Articles

For patients with cutaneous squamous cell carcinoma who refuse surgery as a treatment for their disease, systemic therapies like cemiplimab, nivolumab, avelumab, and pembrolizumab can still improve outcomes, explained Asim Amin, MD, PhD, a medical oncologist, Levine Cancer Institute. Atrium Health during a Targeted Oncology Case-Based Peer Perspectives event.

Early-Phase Trial Data of EGFR Inhibitors Lead to Successful Use of Osimertinib in Resected EGFR+ NSCLC

January 10, 2021

Clinical Articles

Osimertinib has been a successful therapy for the treatment of EGFR-positive non–small cell lung cancer, surpassing the effects of chemotherapy. In he adjuvant setting, physicians questions when and how to use osimertinib.

Trials Conducted in Unresectable Locally Advanced Lung Adenocarcinoma Show Path for Treatment

January 09, 2021

Clinical Articles

Multiple treatment options exist for patients with unresectable locally advanced lung adenocarcinoma. Zofia Piotrowska, MD, examined the options during a Targeted Oncology Case-Based Peer Perspectives event.

Expert Compares Vismodegib and Sonidegib for Treatment of Infiltrative BCC

January 07, 2021

Clinical Articles

Solly Chedid, MD, led a discussion with a group of peers about the treatment of infiltrative basal cell carcinoma in a 88-year-old patient during a Targeted Oncology Case-Based Peer Perspectives event.

Treating Double-Hit Lymphoma With CAR T-Cell Therapy and Other Drugs

January 04, 2021

Clinical Articles

During a Targeted Oncology Case-Based Peer Perspectives event, Haifaa Abdulhaq, MD, director, Hematology, and associate clinical professor of Medicine at UCSF Fresno discussed the case of a 63-year-old patient with lymphoma with concurrent MYC and BCL2 rearrangements.

Hormonal Therapies Useful in Different Situations for Prostate Cancer

December 15, 2020

Clinical Articles

During a Targeted Oncology Case Based Peer Perspectives event, Daniel J. George, MD, professor of Medicine, professor in Surgery Member, Duke Cancer Institute Department of Medicine Duke University School of Medicine, discuss various hormonal therapies for the treatment of prostate cancer.